Ironwood Pharmaceuticals (IRWD) Income from Continuing Operations (2010 - 2026)
Ironwood Pharmaceuticals (IRWD) reported Income from Continuing Operations of 40772000.0 for Q1 2026, up 209.06% on a YoY basis from 13192394.17 in Q1 2025, and up 124.95% sequentially from 163423000.0 in Q4 2025.
Ironwood Pharmaceuticals (IRWD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Ironwood Pharmaceuticals (IRWD) has 17 years of Income from Continuing Operations data on file, last reported at 40772000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 209.06% year-over-year to 40772000.0; the trailing twelve-month figure through Mar 2026 stood at 58972000.0 (down 149.05% YoY), and the FY2025 full-year result was 137130000.0, down 189.39% from the prior year.
- Income from Continuing Operations rose to 40772000.0 in Q1 2026, from 163423000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 154796000.0 in Q4 2024 to a low of 1089522000.0 in Q2 2023.
- A 5-year average of 50914705.88 and a median of 23599000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 3038.3% in 2023 and surged 2844.07% in 2025, its largest moves.
- Tracing IRWD's Income from Continuing Operations over 5 years: stood at 126514000.0 in 2022, then sank by 215.0% to 145491000.0 in 2023, then jumped by 206.4% to 154796000.0 in 2024, then sank by 205.57% to 163423000.0 in 2025, then surged by 124.95% to 40772000.0 in 2026.
- Business Quant data shows IRWD's Income from Continuing Operations at 40772000.0 in Q1 2026, 163423000.0 in Q4 2025, and 40080000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Ironwood Pharmaceuticals | 619.48 Mn | 399.01 Mn | - | 40.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.77 Mn |
| Dec 31, 2025 | -163.42 Mn |
| Sep 30, 2025 | 40.08 Mn |
| Jun 30, 2025 | 23.60 Mn |
| Mar 31, 2025 | -37.39 Mn |
| Dec 31, 2024 | 154.80 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | -860,000.00 |
| Mar 31, 2024 | -4.14 Mn |
| Dec 31, 2023 | -145.49 Mn |
| Sep 30, 2023 | 13.93 Mn |
| Jun 30, 2023 | -1.09 Bn |
| Mar 31, 2023 | 45.71 Mn |
| Dec 31, 2022 | 126.51 Mn |
| Sep 30, 2022 | 50.32 Mn |
| Jun 30, 2022 | 37.08 Mn |
| Mar 31, 2022 | 38.80 Mn |
| Dec 31, 2021 | 41.38 Mn |
| Sep 30, 2021 | 55.85 Mn |
| Jun 30, 2021 | 391.27 Mn |